Drawing from his presentation at the AAD 2025 Annual Meeting, Dr. Seneschal reviews the immune mechanisms underlying Vitiligo and explains why long-term maintenance therapy is often necessary to sustain repigmentation and reduce the risk of disease recurrence.
His discussion explores how ongoing immune activity contributes to melanocyte destruction and why continued treatment may be needed even after successful repigmentation.
Topics Covered
- The immune pathogenesis of vitiligo
- How autoimmune processes target melanocytes
- Why vitiligo often requires long-term maintenance therapy
- The relationship between disease mechanisms and treatment strategies
- Clinical implications for preventing relapse after repigmentation
Explore Related Resources